Showing posts with label non-muscle invasive bladder cancer. Show all posts
Showing posts with label non-muscle invasive bladder cancer. Show all posts

Thursday 15 February 2024

Update on current management of NMIBC

 

Theories behind Bacillus Calmette-Guérin failure in high-risk non-muscle-invasive bladder cancer and update on current management


A new article written by Ms. Louise Paramore, Ms. Hanna Maroof and Mr Ahmed Ali, Clinical Lead, from the Department of Urology, Frimley Park Hospital NHS Trust, discusses in depth the mechanisms of action and pathophysiology of BCG, potential theories behind BCG failure, and the scope of novel treatments for this surgical conundrum.

Published on Cancer Pathogenesis and Therapy


Synergo technology was presented in the article as one of the treatment options for patients who develop recurrence during BCG treatment or those who cannot tolerate the side effects.


Synergo technology provides an advanced therapeutic option for NMIBC patients. The treatment is based on local RF and tissue hyperthermia in combination with simultaneously cooled chemotherapy instillation.

RF is delivered locally to the bladder wall via a miniaturised, embedded antenna.

RF has been shown to have a selective effect on cancer cells. Synergo’s powerful combination enables the drug to access those cells and in-between them, resulting in higher cell uptake and a higher rate of DNA bonding.

Wednesday 9 November 2022

Synergo in a rare case of T1 bladder cancer

Synergo® in a rare case of T1 bladder cancer

Bladder cancer is a rare phenomenon in children, with an incidence rate of 0.1-0.4% during the first two decades of their lives.

A recent new article (2022) published in the Journal of Pediatric Urology by Dr. Galia Raisin and Prof. Boris Chartin from Shaare Zedek Medical Center (Jerusalem) summarizes their experience and treatment outcomes in nine children, seven of whom are male (78%).

A single case of high-grade disease (UC pT1) was diagnosed in a 14-year-old girl, a kidney transplant recipient. Due to her immune status, she was ineligible for BCG treatment and therefore received 6 Synergo sessions, with no recurrence to date - at a follow-up of 4 years.

Galiya R, Stanislav K, Jawdat J, Benjamin H, Boris C. Pediatric urothelial bladder neoplasm. J Pediatr Urol. 2022 Jun 30:S1477-5131(22)00293-5. doi: 10.1016/j.jpurol.2022.06.026. Epub ahead of print. PMID: 35871900.





Monday 17 January 2022

Synergo RF-CHT is effective in non-muscle invasive bladder cancer patients in whom standard intravesical treatments have failed and should be considered in patients who are unwilling or unfit to undergo radical cystectomy.

Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer.

We are honoured to share a peer-reviewed article on Synergo published in Cancers 2021 Journal by Iris S. G. Brummelhuis et al. https://pubmed.ncbi.nlm.nih.gov/33498535/

Their work concludes that Synergo is effective in NMIBC patients in whom standard intravesical treatments have failed and should be considered in patients who are unwilling or unfit to undergo radical cystectomy.

Patients characteristics:

299 intensively pretreated patients. Of these, 274 patients who fulfilled induction treatments were included in efficacy analysis. 

BCG-unresponsive NMIBC: 85.4% of the patients (BCG Refractory: 65% and BCG Intolerant 7.7%).

Patients with CIS with or without concomitant papillary tumor: 46.7% of the patients.

Results following Synergo treatment:

For CIS, six-month complete response -rate was 56.0%; and durable response rates were 79.7%, 66.5%, and 40.3% at one-, two- and five-year, respectively. 

Recurrence free survival rates for papillary patients were 77.9%, 57.5%, and 37.2%, at one-, two- and five-year, respectively respectively. 

Patients treated with ablative dose are less likely to develop recurrence (adjusted Hazard Ratio 0.54, p = 0.01), compared to adjuvant dose.


In total, 22 (8.5%) of all patients progressed to MIBC, of whom 20 had a high-grade tumor prior to RF-CHT and all 22 patients previously have been treated with BCG (21 BCG refractory, 1 unknown reason for BCG discontinuation). Eleven (4.3%) patients had distant metastases up to one year after treatment.
During the mean follow-up period of 55.5 months, 80 patients (29.2%) received a radical cystectomy with or without neoadjuvant chemotherapy. The bladder preservation rate for this follow-up period was thus 70.8%.


Medical Enterprises